Awards Nomination 20+ Million Readerbase
Indexed In
  • Open J Gate
  • Genamics JournalSeek
  • Academic Keys
  • JournalTOCs
  • ResearchBible
  • Electronic Journals Library
  • RefSeek
  • Hamdard University
  • OCLC- WorldCat
  • Proquest Summons
  • SWB online catalog
  • Virtual Library of Biology (vifabio)
  • Publons
  • MIAR
  • Euro Pub
  • Google Scholar
Share This Page
Recommended Webinars & Conferences
Journal Flyer
Flyer image

Tamer E Fandy

Tamer E Fandy

Tamer E Fandy
Associate Professor, Department of Pharmaceutical & Administrative Sciences, School of Pharmacy


Dr. Fandy is serving as an assistant professor in the department of pharmaceutical sciences at Albany College of Pharmacy since 2010. After graduation from the school of pharmacy at the University of Southern California with a master degree in 2001, he joined the PhD program in the department of pharmaceutical sciences at the University of Maryland and graduated in 2005. Dr. Fandy Joined the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University as a postdoctoral fellow till 2010. Dr. Fandy is a member of the American Association for Cancer Research and the American Association of Pharmaceutical Scientists and his research focuses on studying the mechanism of action and development of epigenetic modifiers.

Research Interest

Understanding the epigenetic changes associated with tumor initiation and progression is essential for the prevention and treatment of cancer. Changes in DNA methylation and histone modifications have been detected in different types of tumors. Reversal of these changes is associated with tumor arrest and constitutes the basis of epigenetic therapy.  DNA methyltransferase (DNMT) inhibitors and histone deacteylase (HDAC) inhibitors are considered the backbone of epigenetic therapy in cancer and are currently FDA approved for the treatment of myelodysplastic syndrome (MDS) and cutaneous T-cell lymphoma, respectively. My laboratory focuses on understanding the global epigenetic changes associated with DNMT and HDAC inhibitors and the mechanisms of resistance development against these agents.